NCT02216409View on ClinicalTrials.gov

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Solid Tumor
Interventions
DRUG

Hu5F9-G4

Trial Locations (6)

10065

Memorial Sloan-Kettering Cancer Center, New York

49503

START Midwest, Grand Rapids

60637

University of Chicago, Chicago

73104

University of Oklahoma, Oklahoma City

78229

South Texas Accelerated Research Therapeutics, San Antonio

94305

Stanford Cancer Institute, Stanford

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY